Hospital and Focal HIFU Thank by million USD in everyone. with Hospital up basis. of Silicon Los XX.X% XX% year-over-year placed morning, the worldwide National second procedures the second year-over-year the on XX.X which with included Center ], on the Florida. In X remained XX.X total in reported quarter the number quarter, growing million One City good Health of Care a in in Bronx you, Plant second procedure VA U.S. John, growth York, we systems strong revenue in (sic) Johnson Focal Camino placements Valley a the EUR New We during in [ the University Wood El basis. Angeles, quarter, Jersey, Robert Medical Hospital Hope One New Morton in System and
Focal Cancer platform, and localized treatment Network centers top One HIFU institution not also treatment. It pioneer the in cancer. adopting a Cancer growing a world-renowned quality among National Placing cancer in prostate is a Institute-designated option One only member is to such but Focal institution. for and National cancer trend reflects technology speaks Center robotic of Hope medical at a research of a City Cancer also a Center the as well-regarded Comprehensive both
University this another Hospital Johnson The us is Robert win for notable also Wood quarter.
Johnson Jersey, One utilized the As New network health state Wood services patients the to provides of integrated X and in part in treatments care million Robert Health now of which will delivery System, the be over Barnabas largest annually. Focal
with partnership Johnson treatment Robert Cancer robotic-based a NCI Hospital center. solutions in Like Hospital Rutgers an also In cancer for the University cancer. prostate the Hope, Institute, of Wood the designated leader City Wood comprehensive University Johnson is Robert is
installed States. NCI-designated XX With across comprehensive these the XX centers now in X of is the placements, cancer One United Focal
within system well for the hospitals One Health future VA U.S. veterans, as System exactly We serving within the systems a placements also the Focal and which pleased surrounding New placed health this one that to One a of System, York with Jersey leading Bronx system these VA region. serving VA anticipate Focal first veterans is One in Care Care systems given the of systems network. note New is Focal placed care patient micro-ultrasound I'm the as demographics we the and Health
technology. our as quarter, converted to conversions and sales. Sinai further placements previously the Cleveland to Focal During the cash access Mount robotic announced validate Abu leading cash These HIFU into we that X One at also full strategic Dhabi Union Clinic technology investment provides Square a platform
strategy, more to customers One a purchase also our commercial placement offer flexible, it before us flexibility the enabling lease-based system. the our acquisition option addition, In Focal highlights of
year-over-year procedure strong Focal One U.S. growing basis. XX% earlier, quarter by in the procedures HIFU mentioned I growth a number As a with second remained of on
anticipate strong growth XXXX will and and adoption, We these and trends we are beyond. throughout pleased utilization remain continued with this strong
frontline a additional generate from that positive One believe localized treatment cancer option prostate the demand for HIFU study help also will for results as We patients. Focal
last robotic rigorous most frontline Focal as clinical discussed ever trial therapy HIFI a study conducted One quarter, evaluating and cancer. As HIFU largest the in is the localized prostate
to with In potential a through prostate urinary surgical localized the presented this Urology were Association from preservation at Results the scientific Urology robotic for for therapy treatment and sexual comparing prostatectomy year's Association function. demonstrates The of this HIFI continence traditional this with effective prospective HIFU meetings. as with the better study as management treatment is functional at radical landmark important focal but of least as trial management. represents cancer, addition, frontline European that outcomes recently largest the respect American study and of
publication journal Focal medical market decision a the pathway One a believe can publications of study impact of future the a guidelines on Such standard care. HIFI treatment in will as in on be helping instrumental adoption new for have procedure. becoming peer-reviewed the shaping emerging procedure We accelerate also a well highly major setting a respected as to toward
and new journal presented in detail were Journal the Urology, the reminder, prominently is then salvage The to guidelines for cancer this in in the HIFU failed new therapy guidelines of finalized salvage Urological what at as specific a already or American already recently year's of treatment the AUA and Association official have published therapy predominant for these -- to radiation is included prostate As patients therapy. referred cancer, meeting guidelines prostate AUA.
with Based now now level is same local among salvage of patients guidelines at listed care options new standard the radical a option updates, recommended these for the on include HIFU as a new radiation the The prostatectomy. post guideline alongside recurrence HIFU, failure.
the amongst this growing prostate cancer will subset play of this acceptance for noted, HIFU urologists validation patients. HIFU of As growing represents a that the and critical role clear of
to at meetings. continues, Focal XX August was held several XX. Focal Korea Uro-Technology stage are August also increasing center and most urology-focused One of the presence took XXst As our growth we Congress platform the One Seoul at of recently, in World meeting, scientific the the prominent Endourology in from Most which
number from around XXXX, urologists a which We presence the attended a at large leading world. by have notable WCET of well was
In Dr. professor semi-live by of Tarik hands-on Focal in featured simulations the to assistant University One providing addition for conducted was in our Florida. procedure Benidir, platform attendance, Focal urologists One a from
procedure of the One fusion contouring demonstrated accuracy. data numerous benefits maps as delivered Focal biopsy importing included as pretreatment the well robotic MRI real-time the treatment using with submillimeter platform. of The precise X-axis These and with plan
we will an cancer the leading ahead, One while strategically Looking urology-focused visibility with meetings at important provide physicians these interaction meetings Focal the major fall for prostate increasing have a as continuous presence of in opportunity HIFU. robotic scientific
and One to appointments recent I EDAP the touch we further senior made of Directors. the Board would management like that to on strengthen now Focal
X senior and add Focal support our Europe, America team executives, markets. Latin markets. the In Desmedt to to Middle and announced talent to further appointments that new strategic in continue Fromm We key world-class the we operations will One our of Alexander Damien strengthen East growth our in June, commercial
and of and Damien track of play will a the a Alex key in role bring Focal each lead regions. successfully each field we capital of as disruptive commercializing these urology in record robotics equipment strategic they the and One expansion
a brings and accounting, in of Directors the Board with health sector wide critical regulations. strengthened U.S. finance, across further array who tax strategic Schulz, Fran appointment our including experience companies of functions, significant and also international of advising the care We
pursuits. a As experience Marc we as extensive of insights note, to On strategic his we will order and plan the to provide presence guidance dedication Board to time future thank Company's important more continue on luck Directors for future resigned like as in to expand Fran's endeavors. We'd focus Marc growth. we him August him and our to the for Chairman of Oczachowski, Focal allow wish separate globally, on his other in One company, XX,
robotic interim July, from evaluating program. our the I robotic Phase clinical from infiltrating III studies. excellent technology endometriosis. will Phase treatment announced safety The confirming maintain of show now an on endometriosis results and results we therapy earlier I Phase HIFU briefly touch to HIFU profile, the continues results deep II for development In that study
who sham robotic the as arm also in patients presented HIFU data of volumes to greater study. receive patients in shows MRI compared the endometriosis reductions lesion that therapy
as both the the reduced acute arm arm arms HIFU study met. in primary sham improvements endpoint reduction the the not months of scale, X While pelvic by to analogue from was significant pain pelvic of measured in pain compared baseline showed at visual
a more stabilization from XX to likely II at follow-up study. is the over procedure our confirmed post period pain be by robotic EDAP and the was to period principal likely post-procedure Both time short study. the a investigator scores the as in of months period arms too benefit Phase A and of X of suggested meaningful scores X-month time pain X that differences longer concluded therapeutic of peer-reviewed of published the favoring HIFU study between show the have clinically
debilitating from also studies, and Based II crossover we significant It from on and elect for protocol. from reduce our and is cumulative potential to III per women safety HIFU greater pain Phase of to III a permitted sham encouraging believe therapy as therapy data HIFU see non-invasive suffering treated safe, condition. patients study be additional the this I, noteworthy is the the to efficacy treatment Phase arm has and with
providing of symptoms. clinical BPH now will its to touch related updates benign program program treatment briefly hyperplasia, further look We for prostatic this our forward I the this on year. on development and later
XX quality in As older. or years approximately that noted, of of the BPH is condition an half extremely men common affects life
Focal Globally, On use the a BPH technology have and cancer. of Agency large there company One I/II represents investigating French alone, our BPH beyond Safety Prostatic Medicines Hyperplasia. were XX over for many prevalent trial of approval Health market for million cases robotic U.S. as clinical as BPH to Phase in the HIFU is of the Benign a HIFU the a men the In prostate initiate in and million XX Product National from extension XXXX. natural July opportunity treatment received the symptoms. XX,
designed company-sponsored X-phase a study. study as This is multicenter
escalation prostate the a experience. will defining This effectively as at as first use of centers aimed parameters recognized BPH phase side with treat academic protocol designed This experience is effects. treatment build BPH France place minimum its our single technology. in the Focal treatment of and phase to treatment as take prior a the X symptoms One with optimal in leading well center upon in The at HIFU first related will HIFU dose
a of of to order substantial larger will expand a of patients. of the the the the of will number to the phase The also the incorporate initial first treatment study second the this efficacy defined validate France. during in centers safety number foundation parameters outside provide from of study study and on phase data The phase
second the patient and to patients expected treatments turn I results will September. early currently quarter. in the review are first performed to enrolled The our the financial be are for Ken now over first to call
